Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug in Early Symptomatic Alzheimer's Disease (Japan)
jRCT2031220471Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Randomised, double-blind trial of remternetug in Alzheimer's disease (AD) (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Amyloid plaque clearance on amyloid PET at Week 52. Started Feb 2023; status: active, not recruiting.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031220471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220471.